Literature DB >> 33178540

Posterior Fossa Progressive Multifocal Leukoencephalopathy Secondary to Rituximab.

Mounika Guduru1, Venkata Sunil Bendi2, Mariana S Bebawy3, Dinesh Bande4, Abhishek Matta4.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a rare fatal central nervous system disorder characterized by infection-induced demyelination of white matter due to the opportunistic reactivation of John Cunningham virus in an immunocompromised patient. PML is associated with many immune-mediated diseases, lymphoproliferative conditions, and immunosuppressive agents. In this case report, we present a 79-year-old female patient diagnosed with rheumatoid arthritis who developed posterior fossa PML while on rituximab. She presented with subacute cerebellar ataxia, dysarthria, and nystagmus, and her brain MRI showed right pontine and pontocerebellar lesion with diffusion restriction and heterogenous enhancement highly characteristic of PML. Though many cases of PML with rituximab were reported in the literature, our case describes a rare type of PML affecting the posterior fossa in an HIV-negative patient on rituximab.
Copyright © 2020, Guduru et al.

Entities:  

Keywords:  pml; posterior fossa; progressive multifocal leukoencephalopathy; rheumatoid arthritis; rituximab

Year:  2020        PMID: 33178540      PMCID: PMC7652356          DOI: 10.7759/cureus.10888

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  13 in total

Review 1.  Progressive multifocal leukoencephalopathy in autoimmune diseases.

Authors:  Elisabeth Palazzo; Salim Ahmed Yahia
Journal:  Joint Bone Spine       Date:  2012-01-26       Impact factor: 4.929

Review 2.  Rituximab-associated infections.

Authors:  Juan C Gea-Banacloche
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

Review 3.  Progressive Multifocal Leukoencephalopathy.

Authors:  Elena Grebenciucova; Joseph R Berger
Journal:  Neurol Clin       Date:  2018-11       Impact factor: 3.806

4.  Neuromyelitis optica spectrum disorders in Iran.

Authors:  Sharareh Eskandarieh; Saharnaz Nedjat; Amir Reza Azimi; Abdorreza Naser Moghadasi; Mohammad Ali Sahraian
Journal:  Mult Scler Relat Disord       Date:  2017-10-09       Impact factor: 4.339

5.  Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.

Authors:  David B Clifford; Beau Ances; Craig Costello; Shari Rosen-Schmidt; Magnus Andersson; Deborah Parks; Arie Perry; Raju Yerra; Robert Schmidt; Enrique Alvarez; Kenneth L Tyler
Journal:  Arch Neurol       Date:  2011-05-09

6.  The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.

Authors:  Fabian Zohren; Diamandis Toutzaris; Viola Klärner; Hans-Peter Hartung; Bernd Kieseier; Rainer Haas
Journal:  Blood       Date:  2008-01-30       Impact factor: 22.113

7.  Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

Authors:  Kenneth R Carson; Andrew M Evens; Elizabeth A Richey; Thomas M Habermann; Daniele Focosi; John F Seymour; Jacob Laubach; Susie D Bawn; Leo I Gordon; Jane N Winter; Richard R Furman; Julie M Vose; Andrew D Zelenetz; Ronac Mamtani; Dennis W Raisch; Gary W Dorshimer; Steven T Rosen; Kenji Muro; Numa R Gottardi-Littell; Robert L Talley; Oliver Sartor; David Green; Eugene O Major; Charles L Bennett
Journal:  Blood       Date:  2009-03-05       Impact factor: 22.113

Review 8.  Progressive multifocal leukoencephalopathy: current treatment options and future perspectives.

Authors:  Dejan Pavlovic; Andriani C Patera; Fredrik Nyberg; Marianne Gerber; Maggie Liu
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

9.  Asymptomatic reactivation of JC virus in patients treated with natalizumab.

Authors:  Yiping Chen; Evelyn Bord; Troy Tompkins; Janice Miller; Chen S Tan; R Philip Kinkel; Marion C Stein; Raphael P Viscidi; Long H Ngo; Igor J Koralnik
Journal:  N Engl J Med       Date:  2009-09-10       Impact factor: 91.245

Review 10.  Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review.

Authors:  Chandrashekar Bohra; Lubomir Sokol; Samir Dalia
Journal:  Cancer Control       Date:  2017 Oct-Dec       Impact factor: 3.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.